IGC Expands Phytocannabinoid IP Portfolio with Patent Filing for Method & Composition for Treating Seizure Disorders
June 20 2016 - 8:00AM
India Globalization Capital, Inc. (NYSE:IGC) announces today that
it has filed a patent related to compositions and methods for
treating multiple types of seizure disorders and epilepsy for both
humans and animals. It involves the utilization of a
combination of Phytocannabinoid Cannabidiol (CBD), a Hydantoin
anticonvulsant drug and other compounds that affect the metabolism
of CBD and Hydantoin drugs.
Approximately 50 million people worldwide are affected by
Epilepsy (Sanders, 2003). Epilepsy is thought to be due to
multiple factors that include Sodium, Potassium, GABA (gamma amino
butyric acid) and NMDA (N-Methyl-d-aspartate). It is believed
that to maximally control Epilepsy, modulation of one or more of
these receptors is required and that mono therapy is adequate in up
to 25% of patients.
Mr. Ram Mukunda, CEO of IGC commented, “We see a significant
opportunity in phytocannabinoid-based therapies and this filing
complements our portfolio which encompasses the indications of
Pain, Medical Refractory Epilepsy and Cachexia. Our plan is to
evaluate pre-clinical measures such as testing and toxicity with a
specialized firm in Israel to potentially capture cost efficiencies
as we continue to build our phytocannabinoid-based based
bio-pharmaceutical and nutraceutical IP assets.”
About IGC
In the United States, we develop phytocannabinoid-based
therapies and build state-of-the art farming facilities that we can
eventually use to grow and extract pharmaceutical grade
phytocannabinoids. IGC has several patent filings for the
indications of Pain, Medical Refractory Epilepsy and Cachexia using
cannabinoids. Internationally, IGC engages in leasing, trading and
managing infrastructure projects. We are based in Bethesda,
Maryland.
Our website: www.igcinc.us. Twitter @IGCIR
Facebook.com/IGCIR/
Forward-looking Statements:
Some of the statements contained in this press release that are
not historical facts constitute forward- looking statements under
the federal securities laws. Forward-looking statements can be
identified by the use of the words "may," "will," "should,"
"could," "expects," "plans," "anticipates," "believes,"
"estimates," "predicts," "intends," "potential," "proposed," or the
negative of those terms. These statements are not a guarantee
of future developments and are subject to risks, uncertainties and
other factors, some of which are beyond IGC's control and are
difficult to predict. Consequently, actual results may differ
materially from information contained in the forward-looking
statements as a result of future changes or developments in our
business, our acquisition and diversification strategy, our
competitive environment, and governmental, regulatory, political,
economic, legal and social conditions. Except as required by
federal securities laws, IGC undertakes no obligation to publicly
update any forward- looking statements, whether as a result of new
information, future events, or otherwise. Other factors and risks
that could cause or contribute to actual results differing
materially from such forward- looking statements have been
discussed in greater detail in IGC's Form 10- K for fiscal year
ended March 31, 2015, and in subsequent reports filed with the U.S.
SEC.
Contact:
Claudia Grimaldi
Phone: 301-983-0998